Defining 'Normal' Liver Function Tests & FibroScan Values in Pregnancy

Status Not yet recruiting

Clinical Trial Summary

The main aim of this single-site prospective study is to use serum liver function tests and FibroScan as assessment tools to measure liver disease in pregnant women with or without liver disease at King's College Hospital. This will be assessed during each trimester of pregnancy. FibroScan will assess liver stiffness in these participants and will be used as a surrogate marker for fibrosis.

Clinical Trial Description

Approximately 500 pregnant participants above the age of 16 years will be enrolled into this study, which will occur over an 18-month period (February 2019 to August 2020).

In this prospective cohort study, pregnant participants with or without liver disease will be identified through clinics at King's College Hospital. Participants attending the antenatal, specialist liver-pregnancy clinic and general liver clinics will be given an information leaflet detailing the study. Participants can be interviewed in a clinic room to answer any queries. The participant is then given the option of consenting and participating in the study during that clinic consultation or to contact us at a future date should they need further time for consideration.

Baseline participant details will be collected as well as any preceding liver diagnosis and other comorbidities.

Once consented, the assessment visits will be as follows.

1. Trimester 1 visit (at week 12 booking ultrasound scan):

- Additional FibroScan after booking scan (ideally 3 hours *fasting will be required before this scan)

2. Trimester 2 visit (at week 20 routine ultrasound scan):

- Additional FibroScan after ultrasound scan (ideally 3 hours *fasting will be required before this scan)

- Blood tests to be taken at this point

3. Trimester 3 visit (if occurs, e.g. in participants with diabetes):

- FibroScan (ideally 3 hours *fasting will be required before this scan)

- Blood tests (liver function tests)

4. Post-partum visit (if occurs):

- FibroScan (ideally 3 hours *fasting will be required before this scan)

- Blood tests (liver function tests)

- Fasting = nothing to eat or drink (except water)

The participants will be followed up during pregnancy and, if required, for 3 months after pregnancy, as per routine Obstetric care. Delivery, maternal and foetal outcomes will also be documented. This information will come from the participant online medical records. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03883789
Study type	Observational
Source	King's College Hospital NHS Trust
Contact	Mussarat N Rahim, MBBSBScMRCP
Phone	02032994241
Email	mussaratrahim@nhs.net
Status	Not yet recruiting
Phase
Start date	April 1, 2019
Completion date	November 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05255042` - Tissue Models for Liver Disease
Completed	`NCT04473482` - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Recruiting	`NCT03773887` - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease	N/A
Recruiting	`NCT00345930` - DILIN - Prospective Study
Completed	`NCT00148031` - Improving Hepatitis C Treatment in Injection Drug Users	Phase 4
Terminated	`NCT00031135` - Total Parenteral Nutrition-Associated Liver Disease	Phase 2
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00222664` - Qidong Hepatitis B Intervention Study	Phase 4
Recruiting	`NCT06195917` - Robotic-assisted Percutaneous Transhepatic Puncture	N/A
Recruiting	`NCT04551742` - Social & Contextual Impact on Children Undergoing Liver Transplantation
Completed	`NCT04782050` - Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Recruiting	`NCT05499585` - Treating Pediatric NAFLD With Nutrition	N/A
Terminated	`NCT03396705` - Liver Regeneration
Completed	`NCT04341012` - Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Recruiting	`NCT05733832` - A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.